Xiaolin Zhang, PhD, discusses findings from the phase 2 study exploring a novel oral agent for the treatment of EGFR-mutated non–small cell lung cancer.
Xiaolin Zhang, PhD
Xiaolin Zhang, PhD, is the chief executive officer of Dizal Pharmaceuticals.
Articles by Xiaolin Zhang, PhD
Latest Updated Articles
Sunvozertinib Shows Promise in Treating Pretreated EGFR+ Lung CancerPublished: July 9th 2024 | Updated: